<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04180813</url>
  </required_header>
  <id_info>
    <org_study_id>1218-0184</org_study_id>
    <nct_id>NCT04180813</nct_id>
  </id_info>
  <brief_title>Real-world Study Comparing the Adherence and Effectiveness of Linagliptin vs. Acarbose</brief_title>
  <official_title>A Non-interventional Study of Patient Medication Adherence and Treatment Effectiveness Among New Users of Linagliptin and Acarbose in the Real-world Clinical Setting in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-interventional cohort study based on newly collected data under routine medical practice
      of a total of 500 Diabetes Mellitus, Type 2 patients
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 4, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of T2DM patients with high medication adherence with MMAS-8 questionnaire</measure>
    <time_frame>24 weeks</time_frame>
    <description>Highly adherent patients were identified with the score of 8 on the scale, medium adherers with a score of &gt;=6 and &lt;8, and low adherers with a score of &lt; 6.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The effectiveness of linagliptin and acarbose on glycemic control evaluated by reducing HbA1c during a 24 week follow-up in two groups</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of T2DM patients achieving a therapeutic glycemic response defined as HbA1c &lt; 7.0% or a lowering of HbA1c ≥ 0.5%</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare the composite endpoint (proportion of achieving HbA1c &lt; 7.0% without gastrointestinal adverse events (GI AEs) and without an investigator defined hypoglycaemic event)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction by Diabetes Treatment Satisfaction Questionnaire (DTSQ) among linagliptin and acarbose initiators. The DTSQ would be completed at routine physician visits since initiation of the drug</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Subjects with Diabetes Mellitus, Type 2</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin</intervention_name>
    <description>drug</description>
    <arm_group_label>Subjects with Diabetes Mellitus, Type 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acarbose</intervention_name>
    <description>drug</description>
    <arm_group_label>Subjects with Diabetes Mellitus, Type 2</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        A total of 500 outpatients with T2DM from 16 sites distributed in different regions in
        mainland China.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient should fully know and understand the content of consent form, and the patient
             is willing and able to sign an informed consent form

          -  Chinese outpatients with confirmed T2DM

          -  Patients of ≥ 18, &lt; 80 years old

          -  Patients currently use metformin monotherapy ≥ 1500 mg/day or maximum tolerable dose
             and whose glucose levels are not adequately controlled

          -  HbA1c ≥ 7% and &lt; 12%

          -  New user* linagliptin or acarbose as combination therapy with metformin ≥ 1500 mg/day
             or maximum tolerable dose *New user defined as a T2DM patient initiating linagliptin
             or acarbose as an add-on therapy.

        These are patients who are on metformin and whose glucose levels are not adequately
        controlled.

        Exclusion Criteria:

          -  Type 2 diabetes mellitus patients who previously used any DPP-4 inhibitor/ GLP-1
             receptor agonist at index date or any AGI at index date, are not eligible to
             participate. Also excluded are patients who currently using any glucose-lowering agent
             as monotherapy other than metformin.

          -  Patients with clinically significant acute major organ or systemic disease or other
             condition judged by the investigator that would create difficulty for the 24-week
             follow-up.

          -  Patients who participated in a clinical trial within 2 months prior to study enrolment
             date.

          -  Patients diagnosed with Type 1 diabetes mellitus, secondary diabetes or gestational
             diabetes.

          -  Current treatment with systemic steroids at time of informed consent or within 6 weeks
             prior to informed consent.

          -  Patients with known significant GI disease as judged by the study physician.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Boehringer Ingelheim</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Civil Aviation General Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junting Duan</last_name>
      <phone>13522997198</phone>
      <email>doctorgw@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>No.731 Hospital of China Aerospace Science &amp; Industry Corp.</name>
      <address>
        <city>Beijing</city>
        <zip>100074</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuming Liu</last_name>
      <phone>13901374771</phone>
      <email>doctorliuyuming@sina.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dongying People's Hospital</name>
      <address>
        <city>Dongying</city>
        <zip>257000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shuping Wang</last_name>
      <phone>15505462053</phone>
      <email>dqwg@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhangjiagang First People Hospital</name>
      <address>
        <city>Suzhou</city>
        <zip>215699</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yezi Sun</last_name>
      <phone>15962386878</phone>
      <email>sunyezi911@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 26, 2019</study_first_submitted>
  <study_first_submitted_qc>November 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2019</study_first_posted>
  <last_update_submitted>July 15, 2020</last_update_submitted>
  <last_update_submitted_qc>July 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Linagliptin</mesh_term>
    <mesh_term>Acarbose</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://trials.boehringer‐ingelheim.com/trial_results/ clinical_submission_documents.html to request access to the clinical study documents regarding this study, and upon a signed &quot;Document Sharing Agreement&quot;.
Also, Researchers can use the following link http://trials.boehringeringelheim.com/ to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.
The data shared are the raw clinical study data sets.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.</ipd_access_criteria>
    <ipd_url>https://trials.boehringer‐ingelheim.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

